Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease (Q78944899)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573817%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

title

Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573817%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

1 reference

Fernand Labrie

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573817%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

publication date

1 December 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573817%20AND%20SRC:MED&resulttype=core&format=json

Molecular and Cellular Endocrinology

18 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573817%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

volume

198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573817%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573817%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

page(s)

77-87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573817%20AND%20SRC:MED&resulttype=core&format=json

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.

18 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

The cost of prostatic cancer in a defined population

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Prostate cancer. Primary hormonal treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men**Supported in part by the National Cancer Institute of Canada; Hoechst AG, Frankf

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Prostate cancer consensus hampered by lack of data

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

1 reference

7 January 2021

Anti-androgens in treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

The burden of prostate cancer from diagnosis until death

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0303-7207%2802%2900371-4

7 January 2021

10.1016/S0303-7207(02)00371-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573817%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

1 reference